When semaglutide changes, the first useful signals are often hunger, food noise, dose timing, and routine drift. GLPme is built to track those signals and turn them into cleaner conversations with your clinician.
Ask your clinician whether you should stay on, taper, switch, restart later, or use another maintenance strategy. The right answer depends on why you are changing treatment and whether Ozempic is being used for type 2 diabetes, cardiovascular risk, obesity treatment, or another condition.
Bring concrete questions: What amount of regain should trigger a follow-up? Which labs or markers should be monitored? What symptoms should make you call sooner? If you plan pregnancy, when should medication stop? If cost or coverage is the problem, are there safer alternatives than stretching doses alone?